Omega Therapeuticsの空売り状況は、投資家がOmega Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Omega Therapeutics (OTC:OMGAQ) 株価情報, 空売り情報

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.

OMEGA THERAPEUTICS INC by Omega Therapeutics, Inc.

Omega Therapeutics Inc

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $132.56, a high estimate of $153.00, and a low estimate of $110.00. Observing a downward trend, the current average is 4.78% lower than the prior average price target of $139.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322499_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Crocs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $127.00&#x7C;$138.00 &#x7C; 
&#x7C;Laura Champine &#x7C;Loop Capital &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $132.00&#x7C;$122.00 &#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $122.00&#x7C;$125.00 &#x7C; 
&#x7C;Christopher Nardone &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $153.00&#x7C;$144.00 &#x7C; 
&#x7C;Tom Nikic &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $129.00&#x7C;$129.00 &#x7C; 
&#x7C;Jonathan Komp &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $150.00&#x7C;$180.00 &#x7C; 
&#x7C;Robert Drbul &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$155.00 &#x7C; 
&#x7C;Ashley Owens &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $120.00&#x7C;$150.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Crocs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crocs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Crocs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Crocs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CROX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Crocs analyst ratings.</a>
<h2>Delving into Crocs's Background</h2>
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
<h3>Breaking Down Crocs's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Crocs displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.09%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Crocs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 37.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Crocs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 20.72%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Crocs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.75% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.93, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CROX

Assessing Crocs: Insights From 9 Financial Analysts

Across the recent three months, 4 analysts have shared their insights on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $258.75, a high estimate of $265.00, and a low estimate of $240.00. Marking an increase of 0.49%, the current average surpasses the previous average price target of $257.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322492_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Steris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Turkaly &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $265.00&#x7C;$265.00 &#x7C; 
&#x7C;Reni Benjamin &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $265.00&#x7C;$265.00 &#x7C; 
&#x7C;Jacob Johnson &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $240.00&#x7C;$240.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $265.00&#x7C;$260.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Steris. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Steris's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Steris's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Steris showcased positive performance, achieving a revenue growth rate of 5.61% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Steris's net margin is impressive, surpassing industry averages. With a net margin of 12.66%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Steris's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.67% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Steris's ROA excels beyond industry benchmarks, reaching 1.71%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Steris Stock

Across the recent three months, 7 analysts have shared their insights on Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Skechers USA, presenting an average target of $77.0, a high estimate of $90.00, and a low estimate of $62.00. Highlighting a 4.26% decrease, the current average has fallen from the previous average price target of $80.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322485_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Skechers USA is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $62.00&#x7C;$80.00 &#x7C; 
&#x7C;Christopher Nardone &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $70.00&#x7C;$76.00 &#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $77.00&#x7C;$80.00 &#x7C; 
&#x7C;Rick Patel &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $75.00&#x7C;$80.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $80.00&#x7C;$83.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $90.00&#x7C;$92.00 &#x7C; 
&#x7C;JESALYN Wong &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $85.00&#x7C;$72.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Skechers USA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Skechers USA compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Skechers USA's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Skechers USA's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SKX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Skechers USA analyst ratings.</a>
<h2>All You Need to Know About Skechers USA</h2>
Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.
<h3>Understanding the Numbers: Skechers USA's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Skechers USA's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 12.82%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Skechers USA's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Skechers USA's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Skechers USA's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.16%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.45, Skechers USA adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Skechers USA Through 7 Analysts

21 analysts have expressed a variety of opinions on GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for GE Vernova, presenting an average target of $430.57, a high estimate of $500.00, and a low estimate of $370.00. Marking an increase of 3.69%, the current average surpasses the previous average price target of $415.24. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322476_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of GE Vernova among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $425.00&#x7C;$436.00 &#x7C; 
&#x7C;Charles Minervino &#x7C;Susquehanna &#x7C;Announces &#x7C;Positive &#x7C; $370.00&#x7C;- &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $413.00&#x7C;$391.00 &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $445.00&#x7C;$453.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Announces &#x7C;Buy &#x7C; $380.00&#x7C;- &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $420.00&#x7C;$471.00 &#x7C; 
&#x7C;Julian Mitchell &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $427.00&#x7C;$487.00 &#x7C; 
&#x7C;Ben Kallo &#x7C;Baird &#x7C;Announces &#x7C;Outperform &#x7C; $448.00&#x7C;- &#x7C; 
&#x7C;Martin Malloy &#x7C;Johnson Rice &#x7C;Announces &#x7C;Buy &#x7C; $425.00&#x7C;- &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $453.00&#x7C;$453.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Maintains &#x7C;Neutral &#x7C; $380.00&#x7C;$380.00 &#x7C; 
&#x7C;Joe Ritchie &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $500.00&#x7C;$446.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $470.00&#x7C;$420.00 &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Raises &#x7C;Outperform &#x7C; $471.00&#x7C;$420.00 &#x7C; 
&#x7C;Andrew Kaplowitz &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $437.00&#x7C;$361.00 &#x7C; 
&#x7C;Julian Mitchell &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $487.00&#x7C;$420.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $436.00&#x7C;$374.00 &#x7C; 
&#x7C;Joe Ritchie &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $446.00&#x7C;$400.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $420.00&#x7C;$400.00 &#x7C; 
&#x7C;Andrew Obin &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $415.00&#x7C;$380.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $374.00&#x7C;$367.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to GE Vernova. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GE Vernova compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for GE Vernova's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of GE Vernova's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GEV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GE Vernova analyst ratings.</a>
<h2>Delving into GE Vernova's Background</h2>
GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.
<h3>A Deep Dive into GE Vernova's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, GE Vernova showcased positive performance, achieving a revenue growth rate of 5.11% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: GE Vernova's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.58%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): GE Vernova's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.08%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): GE Vernova's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.95% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: GE Vernova's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying GE Vernova: Insights From 21 Analyst Reviews

5 analysts have shared their evaluations of Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $142.6, a high estimate of $150.00, and a low estimate of $129.00. Observing a downward trend, the current average is 0.83% lower than the prior average price target of $143.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322469_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Addus HomeCare is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Constantine Davides &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $150.00&#x7C;$150.00 &#x7C; 
&#x7C;Scott Fidel &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $142.00&#x7C;$142.00 &#x7C; 
&#x7C;Tao Qiu &#x7C;Macquarie &#x7C;Maintains &#x7C;Outperform &#x7C; $129.00&#x7C;$129.00 &#x7C; 
&#x7C;Raj Kumar &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Overweight &#x7C; $142.00&#x7C;$153.00 &#x7C; 
&#x7C;Ari Wald &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $150.00&#x7C;$145.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Addus HomeCare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Addus HomeCare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Addus HomeCare analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Addus HomeCare</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>A Deep Dive into Addus HomeCare's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Addus HomeCare's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 7.52%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Addus HomeCare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Addus HomeCare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.04%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Addus HomeCare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.52%, the company showcases efficient use of assets and strong financial health.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.28, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADUS

What Analysts Are Saying About Addus HomeCare Stock

In the current market session, Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) stock price is at $164.31, after a 3.75% decrease. However, over the past month, the company's stock went up by 2.04%, and in the past year, by 48.85%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744322460_0.png" alt="Past Year Chart" />

<h3>A Look at Interactive Brokers Group P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 18.84 in the Capital Markets industry, Interactive Brokers Group Inc. has a higher P/E ratio of 24.63. Shareholders might be inclined to think that Interactive Brokers Group Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744322460_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

News

Intraday Update

Markets

IBKR

P/E Ratio Insights for Interactive Brokers Group

7 analysts have expressed a variety of opinions on Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Dana and provided 12-month price targets. The average target is $18.71, accompanied by a high estimate of $23.00 and a low estimate of $16.00. This current average has increased by 25.91% from the previous average price target of $14.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322459_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Dana by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Spak &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $18.00&#x7C;$20.00 &#x7C; 
&#x7C;Tom Narayan &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $16.00&#x7C;$13.00 &#x7C; 
&#x7C;Dan Levy &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $23.00&#x7C;$18.00 &#x7C; 
&#x7C;Ryan Brinkman &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $20.00&#x7C;$14.00 &#x7C; 
&#x7C;Joseph Spak &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $20.00&#x7C;$18.00 &#x7C; 
&#x7C;Colin Langan &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $16.00&#x7C;$10.00 &#x7C; 
&#x7C;Joseph Spak &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $18.00&#x7C;$11.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dana. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Dana compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Dana's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Dana's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dana analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Dana</h2>
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
<h3>Breaking Down Dana's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Dana's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -6.38%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Dana's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dana's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.69%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.04%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 2.19, Dana faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Dana In The Eyes Of 7 Experts

BofA Securities analyst Robert F. Ohmes reiterated a <a target="_blank" href="https://www.benzinga.com/quote/WMT/analyst-ratings" rel="noreferrer noopener">Buy rating</a> on the shares of Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a price forecast of $120.00.
At the Investment Community Meeting in Dallas, the company <a target="_blank" href="https://www.benzinga.com/news/guidance/25/04/44711688/walmart-maintains-steady-growth-forecast-despite-tariffs" rel="noreferrer noopener">reiterated its full-year fiscal 2026 guidance</a>, initially shared during its fourth-quarter results in February.
While the sales outlook for the first quarter remains intact, Walmart has adjusted its EBIT growth projection for the period to reflect a wider range.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44703031/this-beverage-maker-tobacco-company-and-packaged-food-giant-outshine-in-a-recession" rel="noreferrer noopener">This Beverage Maker, Tobacco Company And Packaged Food Giant Outshine In A Recession</a>
This revision comes amid a weaker product mix early in the quarter, particularly in general merchandise, although trends improved as the quarter progressed.
Additionally, the company is accounting for roughly $200 million in increased casualty-related costs and aims to preserve the ability to adjust pricing strategies in response to potential tariff impacts, which could support accelerated market share growth, said the analyst.
The analyst opined that despite ongoing ambiguity surrounding the scale and rollout of new tariffs, WMT appears better equipped than many peers to manage potential fallout.
The retailer highlighted that more than two-thirds of its U.S. merchandise is sourced domestically. For the rest, China and Mexico represent its primary import partners.
Walmart's strong supplier network, pricing and automation systems, along with efficient inventory management, offer meaningful strategic advantages.
Early-stage growth engines are also beginning to take effect including improved profitability in e-commerce, expansion in digital advertising and Marketplace, pharmacy delivery services, continued momentum in India through Flipkart, and gains at Sam's Club in both the U.S. and China.
Importantly, Walmart has not seen any notable anti-American sentiment across its international markets such as Walmex and Sam's Club China, further supporting its global positioning, noted the analyst.
Walmart's digital advertising revenue, which reached $4.4 billion in fiscal 2025, continues to grow despite economic headwinds. The company benefits from its large omni-channel footprint and increasing third-party marketplace participation.
Walmart's U.S. e-commerce segment turned profitable in the first quarter and is expected to remain profitable throughout the year.
With plans to reach 95% of U.S. households with same-day delivery and expand ultra-fast service, Walmart is also seeing strong gains from digital ads, fintech, automation, and membership programs, the analyst observed.
Price Action: WMT shares closed at $90.61 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44752453/bofa-turns-bullish-on-levi-strauss-with-strong-sales-and-low-china-exposure" target="_blank" rel="noreferrer noopener">Beyoncé Partnership, Strong Sales And Low China Exposure &#8211; Analyst Upgrades Levi Strauss To Buy</a></li>
</ul>
Image via Shutterstock

Price Target

Reiteration

General

Walmart's Resilience Shines With Broad EBIT Forecast And Strong Growth Engines, Analyst Says

Biotech

ARGX

argenx SE Receives FDA Approval Of VYVGART Hytrulo Prefilled Syringe For Self-Injection In Generalized Myasthenia Gravis And Chronic Inflammatory Demyelinating Polyneuropathy

Stocks staged a ferocious <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44720903/nasdaq-100-eyes-strongest-day-since-2008-as-magnificent-seven-add-15-trillion-in-historic-market-rally">rally</a> on Wednesday after President Donald Trump <a href="https://www.benzinga.com/25/04/44729384/trump-pauses-tariffs-after-yields-surge-bond-vigilantes-hit-another-homerun-experts-point-to-bond-market-panic-for-reversal">reversed his ‘reciprocal' tariff policy</a> in response to plummeting markets and alarming bond market activity. 
While most countries are now exempt from the steepest import taxes, a 10% flat tariff remains in effect, and the tariffs on China have increased to 145%.
However, bond yields remain high, and stocks remain significantly below the all-time highs set in February, then fell again on Wednesday. Uncertainty continues to dominate the markets, and the risk of recession remains elevated.
It&#8217;s a great time to invest in dividends rather than capital gains. You can do that while still investing in tech stocks.
Here are five great tech stocks paying huge dividends.
Now, tech stocks aren't usually considered dividend payers, but there are a few with relatively sturdy payouts that investors can use to ride out this storm of uncertainty.
Today, we've compiled a list of four tech companies that have been raising their dividend payouts for at least 10 years. Each company has a dividend yield of at least 2%, a manageable payout rate, fair valuation, and a path to avoiding the most stringent tariffs currently being levied on China.
<h2 class="wp-block-heading">Avnet Inc.&nbsp;</h2>
Avnet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) is a distributor of electronic components, including semiconductors, active and passive components, and other electromechanical parts, as well as design solutions and technical training. The company operates on every continent except Antarctica and is the largest chip distributor in Europe. Avnet's vast market reach should help it avoid the worst of the tariffs, and its valuation looks appealing following a rough showing in 2024.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcmcfLl3ZsWWHoGtw6seHhwWx95e7BOQptusKU6TvTEPpdOGv-20E1IHbachpysrHEXFOZ-p49dyxIX1H8kAmlmUaMxLnRWNPylAaClRBflOb2ddtsMzixfSGXQB60-0pBxMRyz?key=2e8fRf9pKK3lM-HifJLKLjPq" alt="" /></figure>
AVT shares are still underwater for 2025, but the stock trades at just 8.3 times forward earnings with a 0.18 Price-to-Sales (P/S) ratio. The dividend yield is currently 3.17%, and the payout rate is just 37%. Avnet has raised its annual dividend payout for 12 consecutive years and the 12% annualized growth rate over the last three years. The stock also has a 91.81 Value score from Benzinga Edge ratings, indicating a potentially undervalued company with a steady dividend.
<h2 class="wp-block-heading">Cisco Systems</h2>
Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) was the poster child of the dot-com bubble excess as its market cap rose above $500 billion by the turn of the millennium &#8211; a number it's never come close to reaching in the two-plus decades since. It's also been 25 years since the stock made a new all-time high over $77 per share (split-adjusted), although it came close in January this year when shares topped $66. Cisco will never dominate the tech landscape like it did during the dot-com years, but that doesn't mean it&#8217;s still an uninvestable company.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXe5fyzjG6ZB1JA5EMH2BVYHKTjMKC4q4JXlzZ3QaOcIdU6E-qoe_28yCwg-P_QCmTOtPBSwPtFXGwUhEgSqtP_SwP43WBoa5sUMgEQbFuuLowQNwHAyiQ_PRzm95261khbqW2tIXA?key=2e8fRf9pKK3lM-HifJLKLjPq" alt="" /></figure>
Cisco currently yields 3.08% with a 12-year history of raising annual payouts. The dividend payout rate (DPR) is relatively high at 71%, but it&#8217;s still sustainable for a company that sells as much high-margin software as Cisco. The company posted more than $54 billion in sales in the last 12 months but still trades at just 14.6 times forward earnings.
With a focus on cybersecurity software over hardware, the company should be minimally impacted by the China tariffs. Analysts have a consensus Buy rating on the stock with an average price target of $63.43, including an $80 price target from Rosenblatt issued on February 13.
<h2 class="wp-block-heading">Qualcomm Inc.&nbsp;</h2>
Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is an example of a remarkable turnaround story in the market. Like Cisco, Qualcomm was a dot-com darling that rose to unsustainable heights during the bubble. Once the bubble popped in late 2000, Qualcomm shares plummeted and continued making new lows until the great financial crisis in November 2008. However, the stock rallied in the decade following the GFC and finally topped its dot-com bubble high in early 2019.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXc8M0O3izmpY0oKP52vW_Zmz8ljLYJGnyPblxrxL1wCSPo-UmEhwolQsyR5FlAdJehJ9CtZ7sYl7wEhwv_aha7Z66xu_7XO7ioj7rRMJejhIhXA_223nVSvzV5Jz4NyCJCRd6Kp?key=2e8fRf9pKK3lM-HifJLKLjPq" alt="" /></figure>
Qualcomm's focus is on the development and licensing of wireless tech and chips for smartphones. Qualcomm products can be found in nearly every wireless device, and it does more than $40 billion in annual sales. QCOM shares also have a strong and steady dividend, yielding 2.73% with a manageable 36% payout rate. The company has a 22-year history of dividend increases, including a 7% annualized growth rate over the last three years. An affordable valuation backs the dividend; the stock trades at just 11.7 times forward earnings with impressive margins (26% profit margin in the most recent quarter).
Analysts are also bullish, with a $195 average price target indicating an upside potential of 35%. Benzinga Edge also gives Qualcomm a 91.82 Value score, the highest of today's selections.
<h2 class="wp-block-heading">CSG Systems International Inc.&nbsp;</h2>
Our smallest and least known company of the day might hold the most promise. CSG Systems International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGS#NASDAQ">CSGS</a>) runs a software-as-a-service (SaaS) platform specializing in financial management and customer experience solutions. The company aims to help firms in the communications sector optimize their digital footprint while effectively managing revenue, licensing, and infrastructure. CSG Systems has been publicly traded for nearly 30 years but has just a $1.73 billion market cap and does $1.2 billion in annual sales. The company has solid margins (47% gross margin last quarter) and trades at just 12 times forward earnings.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfO3fvRSZ0Hspa09BnDdqv3XMwLZ__tfsZtMRv6E7cFzlwqla3nOJqjUrmNjceyHCfBqEhPmcDw2OWeps75UEMUXpE9neBnEOgRE-rwnrElVSw2TmcZhBezalvDUEZLlz3NJE8Axg?key=2e8fRf9pKK3lM-HifJLKLjPq" alt="" /></figure>
Small and mid-cap companies are usually known for substantial dividends, but CSG Systems is an exception. The stock currently yields 2.13% and has a healthy 42% dividend payout rate. Despite its relatively small stature, CSGS has raised its annual payout for 12 consecutive years with a 6.3% annualized growth rate over the last three.
Unlike the rest of the market, CSGS shares are still positive year-to-date, including an impressive 17% gain over the last three months. Even during the worst of the tariff tantrum, the stock only dropped from $61 to $56 before rebounding back above $60 when the tariffs were withdrawn. This stability during the madness is likely why CSGS scored a 90.51 Momentum ranking from Benzinga Edge &#8211; shareholders barely noticed the disturbance!
<h2 class="wp-block-heading">3 New Trade Ideas For Monday</h2>
You can get special access to a deep-dive analysis into the upcoming week and events that could drive the markets and three trade ideas you can take advantage of as early as opening bell. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2">HERE</a> now to ensure you don't miss another round of trades.
Photo: Shutterstock

Opinion

Tech

Trading Ideas

CSCO

CSGS

QCOM

5 Tech Stocks With Surprisingly Strong Dividends

Retractable Technologies Reduces Its Workforce By ~ 7%. The Reduction Is Expected To Save An Estimated $1.6M In Annual Wages And Benefits, Or Approximately 7.8% Of Total Estimated Workforce Costs

KEYS

Keysight Technologie Announces The Pricing Of An Underwritten, Registered Public Offering Of Its Senior Unsecured Fixed Rate Notes In An Aggregate Principal Amount Of $750M

PAVS

Paranovus Entertainment Technology Receives Letter From Nasdaq Regarding Late Filing Of Form 6-K Reporting Interim Financial Information

On Thursday, BofA Securities analyst Christopher Nardone upgraded Levi Strauss &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) <a target="_blank" href="https://www.benzinga.com/quote/LEVI/analyst-ratings" rel="noreferrer noopener">from Neutral to Buy rating</a> and raised the price forecast from $17.00 to $20.00.
The analyst cited the stock's 38% drop from last year as a compelling entry point and highlighted Levi's strong sales trends, conservative revenue guidance, low exposure to China, and improving wholesale performance.
With a solid balance sheet and diversified supply chain, the analyst raised the price forecast, applying an 8x multiple on fiscal 2026 EV/EBITDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44703031/this-beverage-maker-tobacco-company-and-packaged-food-giant-outshine-in-a-recession" rel="noreferrer noopener">This Beverage Maker, Tobacco Company And Packaged Food Giant Outshine In A Recession</a>
The analyst views LEVI as a standout brand in uncertain times, thanks to its growing global appeal and dominant position in the denim market.
The company is expanding beyond denim into categories like dresses, skirts, and outerwear, aiming to increase its reach in women's apparel.
A partnership with Beyoncé continues to fuel brand buzz, while strong direct-to-consumer trends in key regions suggest global market share gains.
LEVI delivered a <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44674732/levi-strauss-shares-rise-after-mixed-q1-results-details" rel="noreferrer noopener">strong fiscal first quarter</a>, with solid holiday sales driving improved revenue and margins. Net organic sales excluding FX, Denizen, footwear, and extra weeks rose 9%, though growth tapered as the quarter progressed.
Management reiterated its 3–4% annual growth outlook, which the analyst views as cautious. Encouragingly, March trends rebounded, and the margin trajectory appears well-positioned against peers forecasting stronger second-half recoveries.
LEVI's wholesale segment is showing positive momentum, with two straight quarters of U.S. growth. In Europe, first-quarter wholesale declined due to distribution center transitions, but order book strength suggests a return to growth in the second quarter.
LEVI is temporarily benefiting from a 90-day tariff reprieve, but the company appears resilient if trade tensions flare again, the analyst observed.
With limited exposure to China in its production and just 40% of sales tied to the U.S., LEVI is insulated from significant disruption.
LEVI's strong balance sheet is a key advantage amid economic uncertainty. With net leverage at just 0.2x, the company is in a far better position than many peers.
This financial flexibility allows LEVI to maintain dividends, continue share buybacks, and reinvest in growth positioning it well should macro conditions worsen, said the analyst.
Price Action: LEVI shares closed lower by 2.75% to $14.52 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44734345/why-home-furnishing-brand-lovesacs-stock-is-surging-today" target="_blank" rel="noreferrer noopener">Why Is Home Furnishing Brand Lovesac's Stock Surging Today?</a></li>
</ul>
Photo by DJSully via Shutterstock

Analyst Color

Upgrades

Movers

LEVI

Beyoncé Partnership, Strong Sales And Low China Exposure - Analyst Upgrades Levi Strauss To Buy

At the 2025 Manila International Auto Show, VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) officially <a target="_blank" href="https://www.media-outreach.com/news/philippines/2025/04/10/374614/vinfast-launches-vf-6-b-suv-and-introduces-free-ev-charging-program-in-the-philippines/" rel="noreferrer noopener">launched </a>the VF 6, its newest B-segment electric SUV, in the Philippines.
The VF 6 comes in two trims—Eco and Plus—priced at PHP 1,419,000 ($24,751) and PHP 1,610,000 ($28,074). Deliveries of the Eco variant will begin in May 2025.
Pham Sanh Chau, CEO of VinFast Asia,&nbsp;said, "We hope it will replicate its segment-leading success in Vietnam and receive the same enthusiastic response as seen in the European market."
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44738776/versace-goes-prada-capris-big-exit-sparks-fashion-power-shift" rel="noreferrer noopener">Versace Goes Prada: Capri's Big Exit Sparks Fashion Power Shift</a>
As part of its green mobility push, VinFast introduced a free EV charging program via the V-GREEN network, valid until May 1, 2027. The company plans to roll out 15,000 charging ports nationwide this year, ensuring accessible charging infrastructure for all users.
"Together with VinFast and our local partners, we're working toward a greener and more sustainable transportation future for Filipino communities," said Nguyen Thanh Duong, CEO of V-GREEN.
VinFast is also offering an attractive buyback program covering up to 90% of the vehicle's original value, along with a 7-year/160,000 km warranty. In addition, the brand is working with partners like Motech and JIGA to establish 100 authorized service centers by year-end.
As part of its strategy for the Indian market, VinFast has already commenced construction of its manufacturing facility in Tamil Nadu, per a <a target="_blank" href="https://auto.economictimes.indiatimes.com/news/passenger-vehicle/vinfast-eyes-indias-growing-ev-market-with-vf6-premium-suv/120120346" rel="noreferrer noopener">report </a>by ET Auto.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, VFS stock has lost over 27% in the past year.
Price Action: VFS shares closed at $2.92 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44731044/jim-cramer-says-pre-market-slide-driven-by-profit-takers-shorts-are-trying-to-figure-whether-to-operate-on-nvidia-avgo-aapl" target="_blank" rel="noreferrer noopener">Jim Cramer Says Pre-Market Slide Driven By Profit-Takers: ‘Shorts Are Trying To Figure Whether To Operate On Nvidia, AVGO, AAPL'</a></li>
</ul>
Photo by VanderWolf Images on Shutterstock

Equities

What's Going On With VinFast Auto Stock On Thursday?

ServiceNow, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) is one of the weaker performers in Goldman Sachs analyst <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8db85e9300015f1ae0/kash-rangan">Kash Rangan&#8217;s coverage group</a>.
Rangan maintained a Buy rating on the company and lowered his <a href="https://www.benzinga.com/quote/NOW/analyst-ratings" target="_blank" rel="noreferrer noopener">price target to $1,050 ($1,200 prior) on Thursday</a>.
ServiceNow has been one of the weaker performers in Rangan&#8217;s coverage group year-to-date (-22% versus coverage average -14%) as investors grapple with sub-20% fiscal 2025 guidance, the potential rationalization of PubSec IT spending, and knock-on effects from tariff policy volatility. 
Regarding the fiscal first quarter, the analyst noted ServiceNow could deliver +20.2% CC Subscription Revenue growth (modestly above guidance for +19.5% to +20%) and CC cRPO growth in line with guidance (+20.5%).
Also Read: <a href="https://www.benzinga.com/25/03/44218665/servicenow-eyes-3-billion-ai-deal-targets-boost-from-moveworks-chatbot-tech" target="_blank" rel="noreferrer noopener">ServiceNow Eyes $3 Billion AI Deal, Targets Boost From Moveworks Chatbot Tech</a>
While fiscal first-quarter guidance likely contemplated ongoing PubSec dynamics and closed before any tariff-related announcements, Rangan noted there may be some risk to fiscal second-quarter and fiscal 2025 guidance.
The analyst noted ServiceNow&#8217;s potential to modestly reduce growth expectations in response to predominantly tariffs and PubSec-related demand volatility (though the 90-day tariff pause adds further complexity).
However, with ServiceNow -29% off all-time highs (and at 33x EV/FCF calendar 2026), Rangan noted the stock provides an attractive entry point, notwithstanding the turbulent macro period.
ServiceNow is the standard for selling on customer value, amplified by its expanding AI portfolio (AI ACV &gt;$200 million) and recent Moveworks acquisition. It has consistently supported a growing share of IT budgets.
Furthermore, ServiceNow offers a strong and expanding free cash flow margin profile (&gt;30%) and maintains a solid balance sheet, meeting the key characteristics of a defensive software asset while still providing a bend toward high growth at scale.
Rangan noted ServiceNow as a resilient software asset that is facing macro uncertainty. However, while the analyst expects fiscal first-quarter results to largely be shielded from the volatility of recent tariff news, he noted the potential for fiscal second-quarter and fiscal 2025 guidance to be impacted by the evolving macro backdrop. 
Tariff uncertainty will likely cause enterprises to reassess IT budgets, spending priorities, and hiring plans, Rangan notes. 
Even following the announcement of the recent 90-day pause, the potential for ServiceNow to reduce forward expectations for revenue and cRPO growth modestly, he adds. Expect some enterprises to be more reluctant to sign large, transformational software deals in the interim, given a lack of clarity around what shape tariff policy will take.
The analyst noted that ServiceNow provides an attractive entry point, notwithstanding the turbulent macro environment. ServiceNow is the standard for selling on customer value, with clear ROI and efficiency gains, all of which are amplified by its growing AI portfolio.
Rangan projected first-quarter revenue of $3.09 billion and adjusted EPS of $3.93.
Price Action: NOW stock is down 5.19% at $783.49 by Thursday&#8217;s close.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44674813/if-tariffs-shift-customer-spending-priorities-these-software-stocks-could-face-slow-growth" target="_blank" rel="noreferrer noopener">If Tariffs Shift Customer Spending Priorities, These Software Stocks Could Face Slow Growth</a></li>
</ul>

ServiceNow Backed By AI, Strong Cash Flow Despite Tariff Uncertainty: Analyst

TRGP

Targa Resources Declares An Increase To Its Quarterly Cash Dividend To $1.00 Per Common Share For Q1 2025

Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to <a href="https://www.benzinga.com/fda-calendar">phase out animal testing requirements</a>.
What Happened: The FDA on Thursday announced plans to replace&nbsp;animal testing in the development of monoclonal antibody therapies and other drugs with human-relevant methods.
The FDA said it will phase out animal testing requirements in favor of AI-based computational models of toxicity and cell lines and organoid toxicity testing. Implementation is expected to begin immediately.
Health care tech and AI-powered biotech stocks making the biggest moves after the bell include Certara Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>), Schrodinger Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>), Simulations Plus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) and Absci Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>). All of the aforementioned names were up between 15% and 25% in Thursday&#8217;s after-hours session at the time of writing, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,&#8221; said Martin Makary, commissioner of the FDA.
&#8220;By leveraging AI-based computational modeling, human organ model-based lab testing and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&amp;D costs and drug prices.&#8221;
The policy changes will help improve the overall process by introducing advanced computer simulations, human-based lab models and regulatory incentives. The change is also expected to result in faster drug development. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44751312/wall-street-on-edge-bank-earnings-inflation-data-consumer-sentiment-set-stage-for-friday-fireworks">Wall Street Braces For High-Stakes Friday With Bank Earnings, Inflation Data, Consumer Sentiment In Focus</a></li>
</ul>
Photo: Tada Images/Shutterstock.

Government

Regulations

Health Care

After-Hours Center

ABSI

CERT

RXRX

SDGR

Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements

Rosenblatt Securities analyst Steve Frankel <a href="https://www.benzinga.com/quote/IMAX/analyst-ratings" target="_blank" rel="noopener">reiterated a Buy rating</a> on the shares of IMAX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) on Wednesday, with a price forecast of $35.00.
Ahead of IMAX&#8217;s upcoming first-quarter earnings report, the analyst has raised the forecasts to better align with consensus, citing strong box office performance. 
Despite concerns about potential <a href="https://www.benzinga.com/25/04/44708103/why-investors-should-watch-chinas-service-trade-amid-us-tariff-escalation-disney-and-imax-most-impacted" target="_blank" rel="noopener">Chinese restrictions on Hollywood films</a>, IMAX&#8217;s first-quarter global box office hit $280 million, far surpassing previous projections of $230 million. This was thanks to the massive success of Ne Zha 2, which grossed $2.145 billion globally, with $2.09 billion from China alone.
The film generated $162.6 million for IMAX, ranking among the company's top six highest-grossing titles and top three by ticket admissions.
Regionally, first-quarter box office figures showed a mixed picture: North America declined 46% year over year to $51 million, while Greater China surged 135% to $167 million. The rest of the world dropped 35% to $62 million.
Reflecting these results, the first-quarter earnings estimates are revised up to $82.7 million in revenue and $24.3 million in earnings, approaching the consensus of $83.5 million and $28.5 million. The updated full-year estimates of $420.0 million/$164.1 million compare to a consensus of $405.9 million/$156.3 million.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44703031/this-beverage-maker-tobacco-company-and-packaged-food-giant-outshine-in-a-recession">This Beverage Maker, Tobacco Company And Packaged Food Giant Outshine In A Recession</a>
IMAX shares declined earlier in the week following reports suggesting China might limit Hollywood film imports amid ongoing trade tensions. However, there has been no official confirmation or coverage from major Chinese media outlets.
Given the importance of moviegoing to China's broader economic sectors, such as retail and real estate, the analyst doubts the government would take actions that could harm the exhibition industry.
If China limits Hollywood film imports, IMAX can pivot by showcasing more domestic films and proven alternatives like Japanese anime, which have performed well in the market. 
The second quarter has started strong, with A Minecraft Movie surpassing expectations globally, noted Frankel.
With six Filmed for IMAX titles scheduled this quarter, including Thunderbolts and Mission Impossible: The Final Reckoning, the company is positioned for potential upside beyond its $265 million global box office estimate.
The shift toward premium movie formats is also boosting IMAX's business. The company revealed key expansion deals, including <a href="https://www.benzinga.com/news/contracts/25/04/44603254/amc-expands-premium-movie-experience-with-imax-laser-upgrades-in-landmark-deal">AMC's plan to install 12 new IMAX with Laser screens</a> and upgrade 68 existing ones.
IMAX recently expanded its partnership with TOHO Cinemas, adding six new IMAX with Laser locations in Japan, one of IMAX's strongest markets by per-screen revenue. This includes the first dual-IMAX complex outside North America, reflecting growing demand for diverse content.
Frankel observed that IMAX is benefiting from a blockbuster-heavy 2025–2026 slate, tighter cost control (especially in China), and stronger partnerships with studios and streamers.
Price Action: IMAX shares traded lower by 4.51% at $22.43 at last check Thursday. 
Read Next: <a href="https://www.benzinga.com/25/04/44734345/why-home-furnishing-brand-lovesacs-stock-is-surging-today">Why Is Home Furnishing Brand Lovesac&#8217;s Stock Surging Today?</a>
Photo: Shutterstock

Entertainment

IMAX

Strong Slate, Premium Push Fuel IMAX Forecast Upgrades, Says Analyst

Mike Ippolito, co-founder of the financial media company Blockworks, summarized his view on tariffs as a "decades-long psyop" of the American middle class that led to populist blow-back and tariffs as a way to return blue-collar manufacturing jobs<a href="https://www.benzinga.com/government/regulations/25/04/44748635/stocks-bounce-off-session-lows-after-trump-says-china-deal-is-going-to-work-out"> to the United States.&nbsp;</a>
What To Know: Ippolito posted a short video clip from the "Bell Curve" podcast where he laid out his views on the motivation behind the Trump administration's aggressive trade policies: The tariffs are intended to appease the middle-class, ‘Main Street'&nbsp; voter base with promises of returning manufacturing jobs to Americans.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/04/44695907/elon-musk-calls-trump-trade-advisor-peter-navarro-dumber-than-sack-of-bricks-defends-tesla-as-the-most-american-made-cars">Elon Musk Calls Trump Trade Advisor Peter Navarro &#8216;Dumber Than Sack Of Bricks,&#8217; Defends Tesla As &#8216;Most American-Made Cars&#8217; </a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is my view on tariffs in ~40 seconds <a href="https://t.co/6atD5S2JaB">https://t.co/6atD5S2JaB</a>
&mdash; Mippo &#x1f7ea; (@MikeIppolito_) <a href="https://twitter.com/MikeIppolito_/status/1910379106803343611?ref_src=twsrc%5Etfw">April 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"A huge problem in America for a very long time is that we were exporting middle-class jobs overseas. And I think there was a decades-long psyop that ‘That's not the case!' … and it was really disproportionately hurting a large portion in voter base in America," Ippolito said.&nbsp;
Middle class workers eventually grew angry with the exportation of industrial and manufacturing jobs and decided they did not like the people and policies that had moved their jobs overseas.&nbsp;&nbsp;
Ippolito said, "You know what? This is what you get. You reap what you sow. You did not solve this problem, you gaslit this huge portion of the population."&nbsp;
The pressure had built up and exploded out in the form of populist policies and tariffs designed to reshore manufacturing and return product manufacturing to the United States in an attempt to please ‘Main Street' American voters.&nbsp;&nbsp;
Ippolito concluded his theory with the idea that Trump's trade policies are intended to move the focus from Wall Street to Main Street.&nbsp; It remains to be seen which "Street," if any, will benefit from the tariffs.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/04/44667862/oil-crashes-to-60-per-barrel-as-recession-fears-grow">Oil Crashes To $60 Per Barrel As Global Recession Fears Grow&nbsp;</a></li>
</ul>
Image: Shutterstock

Comments

Omega Therapeutics

空売り

Omega Therapeutics (OTC:OMGAQ) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル